Skip to main content
logo
Concord Drugs Limited (BOM:538965)
India flag India · Delayed Price · Currency is INR
70.40
-2.49 (-3.42%)
At close: Aug 17, 2026

Concord Drugs Financials Overview

Millions INR. Fiscal year is Apr - Mar.

Revenue & Profits
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
860.69787.37452.45449.25520.81590.43
Revenue Growth
82.51%74.02%0.71%-13.74%-11.79%14.77%
Gross Profit
129.28110.9195.98111.92104.85164.73
Operating Income
44.3731.5327.0424.8729.4639.14
Net Income
20.5110.553.364.729.8615.94
Earnings Per Share
1.720.950.340.471.061.82
EPS Growth
305.70%182.57%-28.47%-55.57%-41.87%-51.47%

Cash & Debt
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Investments
7.517.512.251.760.990.65
Total Debt
145.08145.08192.44175.19169.65164.34
Net Cash (Debt)
-137.58-137.58-190.18-173.42-168.65-163.69
Net Cash Growth
------
Net Cash Per Share
-11.53-12.39-19.02-17.34-18.11-18.72

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
--67.6637.227.9216.637.74
Capital Expenditures
--11.67-23.33-10.18-8.57-24.56
Free Cash Flow
--79.3313.89-2.268.06-16.82
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
15.02%14.09%21.21%24.91%20.13%27.90%
Operating Margin
5.16%4.00%5.98%5.54%5.66%6.63%
Pretax Margin
3.32%1.87%1.53%1.40%2.40%3.81%
Profit Margin
2.38%1.34%0.74%1.05%1.89%2.70%
FCF Margin
--10.08%3.07%-0.50%1.55%-2.85%

Valuation
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingAug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PE Ratio
40.9487.7092.4574.4725.9515.91
P/FCF Ratio
--22.37-31.71-
PS Ratio
1.081.180.690.780.490.43